View profile

FarmaKology Newsletter - Issue #5

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


April 10 · Issue #5 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “”, and happy to have you featured on our newsletter!

Today's Startup
Validic  is the healthcare industry’s premier technology platform for convenient, easy access to digital health data from best-in-class clinical and remote-monitoring devices, sensors, fitness equipment, wearables and patient wellness applications. Validic’s mission continues to be helping our healthcare clients and integrations thrive in this transformational industry.
Ra Pharmaceuticals, announced the successful completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG).
Medicines Discovery Catapult integrates Alderley Park’s imaging services and expertise, further enhancing preclinical imaging capabilities.
ReNeuron Group plc , a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has signed an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Co.
FDA explained that this transition will allow biosimilar insulin products and substitutes to come to market for the first time, stimulating competition and hopefully lowering the drug’s prices.
Episode 61 - A Pharmacist in Health Informatics by Rx Radio: Pharmacy's Podcast | Free Listening on SoundCloud
Job Opportunities
How artificial intelligence is transforming medicine
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue